- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07923422
Calcium Hydroxide Versus Triple Antibiotic Paste for Pain After Root Canal Treatment
Comparative Evaluation of Calcium Hydroxide and Triple Antibiotic Paste on Postoperative Pain in Teeth With Symptomatic Apical Periodontitis: A Randomized Clinical Trial
The goal of this clinical trial is to learn whether triple antibiotic paste reduces pain after root canal treatment more than calcium hydroxide in adults aged 18 to 70 years who have a dead (necrotic) tooth with painful infection at the root tip (symptomatic apical periodontitis). The main question it aims to answer is:
Does placing triple antibiotic paste inside the root canal lower pain 72 hours after treatment compared with calcium hydroxide?
Researchers will compare triple antibiotic paste (a mix of three antibiotics: ciprofloxacin, metronidazole and minocycline) with calcium hydroxide, the medicine most commonly placed inside root canals between dental visits, to see which one leads to less pain after treatment.
Participants will Receive root canal cleaning and shaping of the affected tooth Have either calcium hydroxide or triple antibiotic paste placed inside the root canal, decided by chance Rate their pain on a 0 to 10 scale 72 hours after treatment
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Pain after root canal treatment is common in teeth with symptomatic apical periodontitis and is linked to bacteria and their by-products remaining in the complex root canal system. Calcium hydroxide is widely used as an inter-appointment intracanal medicament because of its high alkalinity and antibacterial action, but some bacteria commonly found in infected root canals are resistant to it. Triple antibiotic paste combines ciprofloxacin, metronidazole and minocycline. Together they act against Gram-positive, Gram-negative and anaerobic bacteria, which may reduce the remaining bacterial load and periapical inflammation more effectively.
This is a two-arm, parallel-group randomized clinical trial conducted at the Department of Operative Dentistry and Endodontics, Rehman Medical Institute, Peshawar, Pakistan. Patients are recruited consecutively. Written informed consent is obtained from each patient or guardian. Baseline age, sex, tooth treated and preoperative pain are recorded on a standardized proforma.
Participants are allocated in a 1:1 ratio to the calcium hydroxide group (Group A) or the triple antibiotic paste group (Group B) by permuted block randomization with a block size of 4. The sequence is computer-generated. Allocation is concealed in sequentially numbered, opaque, sealed envelopes opened only after the patient's enrolment.
All teeth receive the same treatment under local anaesthesia and rubber dam isolation. The working length is set with an electronic apex locator and confirmed radiographically. Canals are cleaned and shaped with a rotary nickel-titanium system (ProTaper Gold, Dentsply Sirona) and irrigated with 2.5% sodium hypochlorite. The smear layer is removed with 17% EDTA for 1 minute, followed by a final saline rinse, to improve penetration of the medicament into dentinal tubules. Canals are dried with paper points.
Group A receives calcium hydroxide paste (Metapex or equivalent commercial preparation). Group B receives triple antibiotic paste made from ciprofloxacin, metronidazole and minocycline in a 1:1:1 ratio, mixed with propylene glycol to a creamy consistency. The medicament is placed with a lentulo spiral to working length, and the access cavity is sealed with a sterile cotton pellet and a temporary restoration (Cavit, 3M ESPE). The medicament stays in place for 7 days until the next appointment.
Pain is recorded by the patient on a 0 to 10 Visual Analog Scale at 72 hours after treatment and grouped as no pain (0), mild (1 to 3), moderate (4 to 6) or severe (7 to 10). The sample size of 138 patients (69 per group) was calculated with reference to Narayanan et al. (2022). Data are analysed in SPSS. Mean pain scores are compared between groups with the independent-samples t-test, and pain categories with the chi-square test. Pain category is also stratified by age and gender. A p-value below 0.05 is considered significant.
Your manuscript lists these as two separate steps: EDTA rinse and then medicament placement. Paste the next set of form questions when you reach them.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 4
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Peshawar, Pakistan
- Rehman Medical Institute
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Patients aged 18 to 70 years
- Both males and females
- Teeth with pulp necrosis and a clinical diagnosis of symptomatic apical periodontitis
- Teeth with a closed apex and fully developed roots
- Willing to give written informed consent
Exclusion Criteria:
- Use of antibiotics or analgesics in the 24 hours before treatment
- Previous root canal treatment on the involved tooth
- Teeth with anatomical anomalies, root resorption or incomplete root formation
- Pregnant or breastfeeding women
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: Calcium Hydroxide
Participants received calcium hydroxide paste as the intracanal medicament after cleaning, shaping and EDTA smear-layer removal. The paste was left in the canal for 7 days. |
Calcium hydroxide paste placed in the root canal with a lentulo spiral to working length as an inter-appointment intracanal medicament. |
|
Eksperymentalny: Triple Antibiotic Paste
Participants received triple antibiotic paste (ciprofloxacin, metronidazole and minocycline, 1:1:1, mixed with propylene glycol) as the intracanal medicament after cleaning, shaping and EDTA smear-layer removal. The paste was left in the canal for 7 days. |
Equal parts ciprofloxacin, metronidazole and minocycline mixed with propylene glycol, placed in the root canal with a lentulo spiral to working length as an inter-appointment intracanal medicament. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Postoperative Pain Intensity
Ramy czasowe: 72 hours after treatment
|
Pain intensity was self-reported by participants on a 0 to 10 Visual Analog Scale, where 0 = no pain and 10 = worst imaginable pain. Higher scores indicate worse pain. Mean scores were compared between the calcium hydroxide and triple antibiotic paste groups. |
72 hours after treatment
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Postoperative Pain Severity Category
Ramy czasowe: 72 hours after treatment
|
Number of participants in each pain category, based on the 0 to 10 Visual Analog Scale score: no pain (0), mild (1 to 3), moderate (4 to 6) and severe (7 to 10). Proportions were compared between groups. |
72 hours after treatment
|
Współpracownicy i badacze
Sponsor
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Ból
- Objawy neurologiczne
- Choroby przyzębia
- Choroby jamy ustnej
- Choroby Stomatognatyczne
- Powikłania pooperacyjne
- Procesy patologiczne
- Choroby okołowierzchołkowe
- Choroby szczęki
- Choroby miazgi zębowej
- Choroby zębów
- Martwica
- Zapalenie ozębnej
- Stany patologiczne, oznaki i objawy
- Objawy i symptomy
- Ból, pooperacyjny
- Okołowierzchołkowe zapalenie przyzębia
- Martwica miazgi zębowej
- Chemikalia nieorganiczne
- Aniony
- Jony
- Elektrolity
- Wodorotlenki
- Alkalie
- Związki wapnia
- Wodorotlenek wapnia
Inne numery identyfikacyjne badania
- ERC/2025/123
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .